Drugs / CMR316
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06589219 | Aug 2024 → Jun 2026 | idiopathic pulmonary fibrosis | Calibr, a division of Scripps Research | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMR316 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06589219 ↗ |
| Route | Other | “nebulized administration of CMR316” NCT06589219 ↗ |